The earnings call presented a strong performance in core and complementary business areas, highlighted by consistent growth in ventilation and rapid expansion in sleep therapy and resupply. Strategic acquisitions and positive regulatory changes further bolstered the company's outlook. While there was a noted slowdown in the staffing segment and a slight decrease in gross margin, the overall narrative was one of robust growth and strategic positioning.

Company Guidance

During the second quarter of 2025, Viemed Healthcare reported strong financial performance, driven by strategic initiatives and organic growth. The company's revenue increased by 14.7% year-over-year, with the core ventilation business accounting for 54% of revenues, and the sleep business growing to represent 19% of revenues. Ventilator revenue rose by 5% sequentially and 11% year-over-year, while sleep therapy patients increased by 15% sequentially and 51% year-over-year. The resupply program saw growth of 10% sequentially and 25% year-over-year. Adjusted EBITDA grew by 12% year-over-year to $14.3 million, with an adjusted EBITDA margin of 22.7%. The company also completed a share repurchase program, acquiring 270,000 shares for $1.8 million. Viemed raised its full-year 2025 guidance, projecting net revenues of $271 million to $277 million and adjusted EBITDA of $59 million to $62 million. The company's expansion into maternal health through the acquisition of Lehan Medical Equipment is expected to further diversify its revenue mix and strengthen its market position.

Consistent Growth in Ventilation Business

For the 17th consecutive quarter, Viemed increased its active ventilator patient count. Vent revenue was up 5% sequentially and 11% year-over-year, reinforcing the strength of the core business.

Rapid Growth in Sleep Therapy and Resupply

Sleep therapy patients increased 15% sequentially and 51% year-over-year. New patient setups were up 72% year-over-year. Resupply program saw a 10% sequential and 25% year-over-year growth.

Strategic Acquisition of Lehan Medical Equipment

Acquisition marks entry into the maternal health space, expanding Viemed's addressable market and diversifying the patient base. It's expected to leverage national infrastructure and payer relationships.

Strong Financial Performance and Raised Guidance

Year-over-year revenue increased 14.7% driven by organic growth. The company raised its full-year 2025 guidance for net revenue and adjusted EBITDA, projecting 22% and 18% growth respectively over 2024.

Positive Regulatory Developments

The final rule on NCD eliminates the 'tried and failed' approach on BiPAP, benefiting patients by reducing operational burdens and potentially leading to industry consolidation opportunities.

Viemed Healthcare (VMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	0.09 / -	0.1	―	―	―
Aug 06, 2025	2025 (Q2)	0.09 / 0.08	0.04	100.00% (+0.04)
May 07, 2025	2025 (Q1)	0.06 / 0.06	0.04	50.00% (+0.02)
Mar 10, 2025	2024 (Q4)	0.10 / 0.10	0.09	11.11% (+0.01)
Nov 06, 2024	2024 (Q3)	0.07 / 0.10	0.07	42.86% (+0.03)	―
Aug 07, 2024	2024 (Q2)	0.07 / 0.04	0.06	-33.33% (-0.02)	―
May 06, 2024	2024 (Q1)	0.07 / 0.04	0.04	0.00% (0.00)	―
Mar 06, 2024	2023 (Q4)	0.10 / 0.09	0.06	50.00% (+0.03)	―
Nov 01, 2023	2023 (Q3)	0.10 / 0.07	0.03	133.33% (+0.04)	―
Aug 09, 2023	2023 (Q2)	0.06 / 0.06	0.02	200.00% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$6.45	$6.96	+7.91%
May 07, 2025	$7.27	$6.42	-11.69%
Mar 10, 2025	$7.40	$7.80	+5.41%
Nov 06, 2024	$9.14	$9.00	-1.53%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.